SYD1875

About Byondis

Byondis is a clinical-stage biotech developing a proprietary pipeline of antibody-drug conjugates (ADCs) for oncology, anchored by its lead asset, [vic-]trastuzumab duocarmazine (SYD985). The company leverages its internal ADC platform, including its proprietary linker-payload technology (duocarmycin-based), to create targeted therapies. While it faced a significant setback with a Complete Response Letter from the FDA for its lead candidate in HER2-positive metastatic breast cancer, Byondis continues to advance other pipeline programs and explore strategic options, including partnerships or out-licensing, to realize the value of its technology.

Therapeutic Areas